Scientists dig up new evidence linking GSK's Pandemrix with narcolepsy

A team of Stanford University scientists think they have found a potential reason why GlaxoSmithKline's ($GSK) now-withdrawn flu shot Pandemrix was associated with a spike in narcolepsy cases. In a study published in Science Translational Medicine, the researchers said a protein contained in the H1N1 virus was found in high amounts in GSK's vaccine. A Novartis ($NVS) jab also used in the 2009/2010 swine flu pandemic contained much lower levels of the same protein, they said. More from FierceVaccines

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.